Roivant unveils latest spinout as Pfizer entrusts JAK1/TYK2 to Priovant

Amber Tong

In November, Pfizer disclosed it’s spun out the Phase II dual JAK1/TYK2 inhibitor to a startup formed in collaboration with an unnamed, experienced partner. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roivant unveils latest spinout as Pfizer entrusts JAK1/TYK2 to Priovant

Amber Tong

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

US drugs rely heavily on ingredients made overseas, new report shows

Biotech seed rounds sink to lowest level in years as industry slump drags on

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Roivant un­veils lat­est spin­out as Pfiz­er en­trusts JAK1/TYK2 to Pri­o­vant

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Roivant unveils latest spinout as Pfizer entrusts JAK1/TYK2 to Priovant